Laurion Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Laurion Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9,872	Closed	-$675K	–	1054
2021 Q1	$675K	Buy	+9,872	New	+$798K	﹤0.01%	546
2020 Q3	–	Sell	-5,936	Closed	-$434K	–	1281
2020 Q2	$434K	Sell	5,936 -170,464	-97%	-$9.07M	﹤0.01%	646
2020 Q1	$6M	Buy	+176,400	New	+$8.07M	0.07%	218
2019 Q3	–	Sell	-84,713	Closed	-$3.71M	–	1416
2019 Q2	$3.71M	Buy	+84,713	New	+$4.78M	0.04%	306
2019 Q1	–	Sell	-152,946	Closed	-$5.66M	–	1487
2018 Q4	$5.66M	Buy	+152,946	New	+$5.51M	0.1%	257
2018 Q2	–	Sell	-38,096	Closed	-$981K	–	1758
2018 Q1	$981K	Buy	+38,096	New	+$1.14M	0.01%	844
2017 Q3	–	Sell	-85,625	Closed	-$2.14M	–	2098
2017 Q2	$2.14M	Buy	+85,625	New	+$1.97M	0.01%	791

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Laurion Capital Management's BHVN Position: Q2 2021 in Review

Laurion Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2021, closing a stake of 9,872 shares — an estimated $675K sold.

Laurion Capital Management first reported a position in BHVN in Q2 2017 and held it in 7 quarters. The position peaked at $6M in Q1 2020. 223 funds tracked by Wall St. Rank hold BHVN as of Q2 2021.

Laurion Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2021 after selling out during the quarter.
Laurion Capital Management sold 9,872 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2021, an estimated $675K.
Laurion Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 7 quarters.
Laurion Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $6M in Q1 2020.
223 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.